Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ATP12A | P54707 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989026 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2L3MBTL1CA2 | |
| SCHEMBL29347465 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2L3MBTL1CA2 | |
| SCHEMBL3989029 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2L3MBTL1CA2 | |
| SCHEMBL4092901 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2L3MBTL1CA2 | |
| SCHEMBL28890099 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2L3MBTL1CA2 | |
| SCHEMBL3989031 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2L3MBTL1CA2 | |
| SCHEMBL4425298 | 0.83 | L3MBTL1 (0.45) | HCAR2L3MBTL1CA2ALDH1A1HSD17B10 | |
| SCHEMBL3988831 | 0.83 | L3MBTL1 (0.45) | HCAR2L3MBTL1CA2ALDH1A1HSD17B10 | |
| SCHEMBL18312447 | 0.83 | HCRTR2 (0.33) | HCRTR2 | |
| SCHEMBL4422593 | 0.83 | L3MBTL1 (0.45) | HCAR2L3MBTL1CA2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239812-A1 | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239812-A1 | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-1669353-B1 | Process for preparing alpha, beta - unsaturated esters | DAISO CO LTD (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-7208634-B2 | Oxidation method of primary or secondary alcohol | DAISO CO., LTD. (JP) | 2007-04-24 | — | — | US | disclosed |
| EP-1669353-A1 | Process for preparing alpha, beta - unsaturated ester | DAISO CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20060122434-A1 | Novel oxidation method of primary or secondary alcohol | OSAKA SODA CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1666441-A1 | Oxidation method for primary or secondary alcohols | DAISO CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239812-A1 | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 | MCL1, BCLAF1, BAK1 | HCAR2 4191/4885KEAP1 52/4885NFE2L2 208/4885 |
| US-20060122434-A1 | Novel oxidation method of primary or secondary alcohol | CBR3, CBR1, AOX1 | HCAR2 1519/4885KEAP1 520/4885NFE2L2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.